BONEXS Stock Overview
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr243.80 |
| 52 Week High | kr243.80 |
| 52 Week Low | kr115.00 |
| Beta | 1.03 |
| 1 Month Change | 0% |
| 3 Month Change | 23.98% |
| 1 Year Change | 117.29% |
| 3 Year Change | 246.31% |
| 5 Year Change | n/a |
| Change since IPO | 551.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| BONEXS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.0% |
| 1Y | 117.3% | -19.3% | 6.7% |
Return vs Industry: BONEXS exceeded the UK Biotechs industry which returned -19.3% over the past year.
Return vs Market: BONEXS exceeded the UK Market which returned 6.7% over the past year.
Price Volatility
| BONEXS volatility | |
|---|---|
| BONEXS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BONEXS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BONEXS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 118 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| BONEXS fundamental statistics | |
|---|---|
| Market cap | kr16.05b |
| Earnings (TTM) | kr266.56m |
| Revenue (TTM) | kr655.75m |
60.2x
P/E Ratio24.5x
P/S RatioIs BONEXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONEXS income statement (TTM) | |
|---|---|
| Revenue | kr655.75m |
| Cost of Revenue | kr52.38m |
| Gross Profit | kr603.38m |
| Other Expenses | kr336.82m |
| Earnings | kr266.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 11, 2024
| Earnings per share (EPS) | 4.06 |
| Gross Margin | 92.01% |
| Net Profit Margin | 40.65% |
| Debt/Equity Ratio | 0% |
How did BONEXS perform over the long term?
See historical performance and comparison